Orthometrix, Inc. Forms Alliance with Healthcare Reimbursement Solutions, Inc. to Provide Full Service to Podiatric and Orthopedic Practices Using Its Orbasone(TM) ESWT Pain Relief System to Treat Foot Pain.

WHITE PLAINS, N.Y. -- ORTHOMETRIX, INC. (OTCBB: OMRX) today announced an alliance with Healthcare Reimbursement Solutions, Inc. of Orlando, Florida ("HRSI") to provide health care providers, such as those with Podiatric and Orthopedic practices, using its new Orbasone(TM) Extracorporeal Shock Wave Therapy ("ESWT") Pain Relief System with a broad range of billing advisory services. The Orbasone(TM) ESWT Pain Relief System received market approval from the U.S. Food and Drug Administration in August 2005 for the treatment of chronic plantar fasciitis (foot pain).

The alliance allows purchasers of the Orbasone(TM) ESWT system to avail themselves of HRSI's billing and reimbursement consulting services HRSI's services range from updating known payer information in a provider's geographical area, educational programs in the office on the claim submission process, CPT code descriptions and the preparation of medical necessity letters. In addition, a dedicated reimbursement hotline will be available to Orbasone(TM) ESWT users for one-on-one consulting and assistance with denial and claim review.

Reynald Bonmati, Chairman and Chief Executive Officer of Orthometrix, commented, "Access to reliable billing and reimbursement information has become all the more valuable today to Podiatric and Orthopedic practices as well as Pain Clinics providing ESWT procedures since the new Category III Current Procedural Terminology (CPT) Code 28890 became effective as of January 1. Orthometrix is now providing such service free of charge to purchasers of our Orbasone system."

As a result of this alliance, the purchasers of the Orbasone(TM) ESWT system will also have direct access to additional services provided by HRSI. These include comprehensive turn-key billing and reimbursement services and assistance in coordinating the use of the Orbasone(TM) ESWT system amongst the providers to achieve maximum use and benefit.

Reynald Bonmati further stated, "Our intent is to make ESWT treatment accessible to a larger segment of the U.S. population. This alliance will make it easier for Podiatrists, Orthopedic Surgeons and Pain Clinics to own an Orbasone and has already had a beneficial impact on our sales." According to a survey conducted by the American Podiatric Medical Association in 2000, 38.6 million Americans suffer from plantar fasciitis. The condition particularly affects athletes and the elderly.

About Healthcare Reimbursement Solutions, Inc.

Healthcare Reimbursement Solutions, Inc. has over ten years of experience assisting various clients with the opportunity to sell, perform and receive private payer reimbursement for new technology procedures and treatments such as ESWT, without waiting for permanent coding. These services allows providers the opportunity of an immediate revenue pathway.

About Orthometrix, Inc.

Orthometrix, Inc. markets, sells and services several musculoskeletal product lines used in pharmaceutical research, diagnostic and monitoring of bone and muscle disorders, sports medicine, rehabilitative medicine, physical therapy and pain management.

Our Web addresses are www.orthometrix.net, www.orbasone.com and www.vibraflex.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this release are forward looking statements that involve risk and uncertainties, including, but not limited to, any effect on future financial results from efforts to broaden the Company's position in the rehabilitation, physical therapy and musculoskeletal markets, any potential impact on sales of the Orbasone in North America, and other risks detailed in the documents periodically filed with the Securities and Exchange Commission, specifically the most recent reports on Forms 10-KSB and 10-QSB. These risks and uncertainties could cause actual results to differ materially from those expected and/or contained in the forward-looking statements. Any forward-looking statement made in this release is made as of the date of this release and the Company assumes no obligation, subject to applicable law, to update such forward-looking statement.